{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:13:22Z","timestamp":1790820802095,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1124\/dmd.31.5.565","type":"journal-article","created":{"date-parts":[[2003,4,14]],"date-time":"2003-04-14T13:38:41Z","timestamp":1050327521000},"page":"565-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19"],"prefix":"10.1016","volume":"31","author":[{"given":"Caiping","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent L.","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Trager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan D.","family":"Kharasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.31.5.565_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-9556(25)06598-5","article-title":"Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.","volume":"15","author":"Adedoyin","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.5.565_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/096032719501400108","article-title":"High performance liquid chromatography with ultraviolet detection used for laboratory routine determination of fluvoxamine in human plasma.","volume":"14","author":"Belmadani","year":"1995","journal-title":"Hum Exp Toxicol"},{"key":"10.1124\/dmd.31.5.565_bib3","unstructured":"CDER. Guidance for Industry: in vivo drug metabolism\/drug interaction studies: study design, data analysis and recommendations for dosing and labeling, 1999"},{"key":"10.1124\/dmd.31.5.565_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","article-title":"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.","volume":"34","author":"Crewe","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s002280050580","article-title":"Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.","volume":"54","author":"Hemeryck","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib6","first-page":"207","article-title":"Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities.","volume":"26","author":"Hickman","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.5.565_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.31.5.565_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0009-9236(97)90030-8","article-title":"Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.","volume":"62","author":"Jeppesen","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.31.5.565_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0009-9236(98)90174-6","article-title":"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6 and CYP3A as determined by phenotyping.","volume":"64","author":"Kashuba","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.31.5.565_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-9556(24)15123-9","article-title":"Prediction of pharmacokinetic drug\/drug interactions from in vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.","volume":"28","author":"Kohl","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.5.565_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0090-9556(24)15066-0","article-title":"Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.","volume":"28","author":"Komatsu","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.5.565_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0090-9556(25)07370-2","article-title":"Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction.","volume":"24","author":"Kunze","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.5.565_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-9556(25)00213-2","article-title":"A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.","volume":"8","author":"Kupfer","year":"1980","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.5.565_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mcp.2001.112689","article-title":"Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.","volume":"69","author":"Madsen","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.31.5.565_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0003-2697(85)90177-0","article-title":"Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography.","volume":"151","author":"Meier","year":"1985","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.31.5.565_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0016-5085(83)90026-4","article-title":"Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.","volume":"85","author":"Meier","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.31.5.565_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00004714-200002000-00007","article-title":"Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.","volume":"20","author":"Olesen","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.31.5.565_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/clpt.1994.167","article-title":"Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.","volume":"56","author":"Perucca","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.31.5.565_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003088-199427030-00002","article-title":"Clinical pharmacokinetics of fluvoxamine.","volume":"27","author":"Perucca","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.31.5.565_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2125.1995.tb04422.x","article-title":"Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.","volume":"39","author":"Rasmussen","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s002280050544","article-title":"Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.","volume":"54","author":"Rasmussen","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib22","series-title":"Metabolic Drug Interactions","first-page":"29","article-title":"Industrial viewpoint: application of in vitro drug metabolism in various phases of drug development","author":"Ring","year":"2000"},{"key":"10.1124\/dmd.31.5.565_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1081\/DMR-100101935","article-title":"Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.","volume":"31","author":"Schmider","year":"1999","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.31.5.565_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF01061759","article-title":"Kinetics of drug metabolism inhibition: use of metabolite concentration-time profiles.","volume":"15","author":"Shaw","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.31.5.565_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2125.1992.tb04133.x","article-title":"Inhibitors of imipramine metabolism by human liver microsomes.","volume":"34","author":"Skjelbo","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s002280100373","article-title":"The major fluvoxamine metabolite in urine is formed by CYP2D6.","volume":"57","author":"Spigset","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2125.1998.00670.x","article-title":"Non-linear fluvoxamine disposition.","volume":"45","author":"Spigset","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib28","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","article-title":"Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.","volume":"62","author":"Tran","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.31.5.565_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1994.tb04317.x","article-title":"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.","volume":"38","author":"von Moltke","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2125.1996.tb00019.x","article-title":"In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine.","volume":"42","author":"Xu","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.31.5.565_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0090-9556(24)14917-3","article-title":"Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.","volume":"27","author":"Yamano","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.5.565_bib32","first-page":"415","article-title":"Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.","volume":"70","author":"Yao","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.31.5.565_bib33","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/jps.10179","article-title":"Inhibition-based metabolic drug-drug interactions: predictions from in vitro data.","volume":"91","author":"Yao","year":"2002","journal-title":"J Pharm Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624026680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624026680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.31.5.565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:10:54Z","timestamp":1739873454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624026680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["S0090955624026680"],"URL":"https:\/\/doi.org\/10.1124\/dmd.31.5.565","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.31.5.565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}